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Translational relevance 
 
The biomarker identified in this study, a single nucleotide polymorphism in the CD44 
gene, robustly associates with over 2-fold allelic differences in risk for tumor-related 
death in 3 independent study cohorts that comprise a total of 348 patients with resectable 
pancreatic ductal adenocarcinoma. In contrast to other biomarkers currently in clinical 
use in this tumor type, CD44 SNPrs187115 can be determined before the initiation of any 
treatment by a simple blood test, which is readily available at the time of diagnosis. The 
data presented in this manuscript strongly suggest that CD44 SNPrs187115 could be utilized 
as a biomarker signature in order to identify individuals that are more likely to have a 
good oncologic outcome after surgical treatment and could therefore guide personalized 
treatment decisions. In addition, CD44 SNPrs187115 has the potential to affect the medical 
treatment of the patients with pancreatic ductal adenocarcinoma, particularly modern 
targeted therapies.  
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Abstract 
 
Purpose: Although pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor, 
like other common cancers, it displays a wide range of biology. However, at present, 
there are no reliable tests to predict patients’ cancer-specific outcomes and guide 
personalized treatment decisions. In this study, we aim to identify such biomarkers in 
resectable PDAC by studying single nucleotide polymorphisms (SNPs) in the CD44 
gene, which drives the progression of pancreatic cancer.  
Experimental Design: 348 PDAC patients from three independent cohorts (Switzerland, 
Germany, The Cancer Genome Atlas (TCGA)) who underwent pancreatic resection are 
included in the study. Information on the haplotype structure of the CD44 gene is 
obtained using 1000 Genomes Project data and the genotypes of the respective tagging 
SNPs are determined. Cox proportional hazards models are utilized to analyze the impact 
of SNP genotype on patients´ survival. 
Results: We identify a SNP in the CD44 gene (SNPrs187115) that independently associates 
with allelic differences in prognosis in all study cohorts. Specifically, in 121 Swiss 
patients, we observe an up-to 2.38-fold (p=0.020) difference in tumor-related death 
between the genotypes of SNPrs187115. We validate those results in both the German 
(hazard ratio (HR)=2.32, p=0.044, 101 patients) and the TCGA cohort (HR=2.36, 
p=0.044, 126 patients). 
Conclusions: CD44 SNPrs187115 can serve as a novel biomarker readily available at the 
time of PDAC diagnosis that identifies patients at risk for faster tumor progression and 
guide personalized treatment decisions. It has the potential to significantly expand the 
pool of patients that would benefit from tumor resection.  
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Introduction 
 
The late stage clinical presentation of pancreatic ductal adenocarcinoma (PDAC) 
in more than 80% of patients at the time of diagnosis, the high resistance to radiation- and 
chemotherapy as well as the limited effectiveness of current targeted therapeutic 
approaches result in an exceptionally poor overall prognosis (1-3). Surgery offers at 
present the only chance for a cure but carries a significant morbidity and mortality risk 
and results in varying oncologic outcomes with early recurrence and metastases in some 
individuals and long-term disease-free survival in others (4, 5). It is thought that the 
utilization of the knowledge of the likely oncologic course of an individual´s condition 
and the clinical response to any given therapy could guide a proper patient selection in a 
personalized fashion.  
Such characterization of groups of individuals that are likely to benefit from 
individualized treatment decisions could be made possible by the understanding of 
human germline genetic variation (6, 7). Importantly, this type of genetic information 
about the patient is contained in the germline DNA and can be easily obtained by a 
simple blood or even saliva test before the initiation of any treatment and without the 
need for tumor biopsy. It has the potential to facilitate a personalized decision by an 
interdisciplinary team of oncologists, radiologists and surgeons about which treatment is 
most likely to benefit the patient. This type of personalized medicine is no longer a 
fantasy but a maturing reality. In other cancer types, such as acute lymphoblastic 
leukemia, colorectal, lung and breast cancer, the knowledge of an individual´s germline 
genetic code already affects clinical practice and the genotyping of certain alleles is 
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recommended by the US Food and Drug Administration (FDA) (8). However, despite 
emerging evidence that inherited genetic variation also affects the survival of pancreatic 
cancer patients and could influence the therapy of this dismal disease, no biomarker 
available at the time of diagnosis has been suggested for clinical use in PDAC to this date 
(9, 10). Therefore, in this study, we search for predictive biomarker signatures in PDAC 
patients that underwent tumor resection, which could help interdisciplinary teams make 
individualized treatment decisions.  
To this end, we focus our study on single nucleotide polymorphisms (SNPs) in the 
CD44 gene. This transmembrane glycoprotein is involved in a vast range of cellular 
processes, such as regulation of growth, survival, differentiation, and motility (11). In 
pancreatic cancer, CD44 has been recently shown to affect the invasiveness, progression 
and the metastatic phenotype (12-14). The potential of germline genetic variation in the 
CD44 gene to affect human cancer progression, patient survival and therapy has been 
previously demonstrated (15). Hereby, a chemosensitivity screen has identified a SNP in 
the CD44 gene (SNPrs187115) that associates with allelic differences in cellular responses 
to a large panel of cytotoxic chemotherapeutic agents in cells (on average 2.8-fold 
difference in drug sensitivity (p=8.1×10-24)) and survival of soft-tissue sarcoma patients 
(up-to 2.89 difference in tumor-related death, p=0.011, Cox multivariate analysis) (15). In 
this report, we build upon and expand those findings to search for clinically relevant 
single nucleotide polymorphisms in the CD44 gene that affect the survival of PDAC.   
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Materials and Methods 
 
Swiss patient cohort. 154 patients with pancreatic cancer who were diagnosed in the 
years 2001-2013 at the Institutes of Pathology of the University Hospital of Zurich and 
Cantonal Hospital of Winterthur were included in a biobank-database (Table 1). From 
this database, 121 patients with pathologically confirmed PDAC were retrospectively 
included in the study. Approval from the local ethics committee was obtained. 
German patient cohort. This prospective biobank-database comprises of 253 patients 
who underwent pancreatic surgery at the Department of General, Visceral and 
Transplantation Surgery (University of Ulm, Germany) in the years 2001 to 2007 (Table 
1). From this database, 101 PDAC patients were included in the study. Approval from the 
local ethics committee was obtained. 
The Cancer Genome Atlas (TCGA) cohort. This prospective database comprises of a 
total of 185 pancreatic cancer patients (years of initial pathological diagnosis 2007-2013) 
(Table 1). Thereof, 126 PDAC patients were included in the study. Approval from the 
NIH Data Access Committee was obtained. 
Sample size. The sample size for the PDAC cohorts is based on, and limited by, the 
availability of tissue material for DNA extraction and analysis and the 
histopathological/clinical follow-up data of patients who underwent pancreatic resection. 
From all 3 PDAC cohorts (Swiss, German and TCGA), all patients with pathologically 
confirmed PDAC who underwent pancreatic resection and for whom tumor-free tissue or 
blood and a full clinical dataset was available were included in the study (Table 1). In 
addition, using data from our Swiss discovery cohort, we conducted a power analysis to 
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assess whether we can detect a 2-fold increase in risk (hazard ratio (HR)=2) for CD44 
SNPrs187115. Indeed, we estimated a power of 81.7% for a cohort of 125 patients, which is 
by approximation a common threshold (80%) utilized in clinical trials. 
Control cohort. 498 blood donors (Germans of central European origin; 194 females and 
304 males, ages 19-68 years; median 44.0 years) from whom samples were obtained at 
the German Red Cross Blood Transfusion Service NSTOB (Springe, Germany) were 
included in the study. Approval from the local ethics committee was obtained. 
DNA extraction and sequence analysis. The germline allelic frequency of SNPs was 
determined from blood samples or normal pathologically confirmed tumor-free tissue 
adjacent to the resection specimen. Tissues (fresh-frozen sections or paraffin-embedded) 
and blood samples were stored at -80°C. Genomic DNA was extracted using the QIAamp 
DNA FFPE Tissue-Kit (Cat.no.56404, Qiagen, Hilden, Germany) and the Innuprep 
DNA/Blood DNA mini-kits (AJ Innuscreen, Berlin, Germany). The SNP genotypes 
(rs187115, rs353647, rs11033019, rs10768114, rs2065006, rs1547060, rs3794110, 
rs353630, rs353615, rs353623) were determined by PCR amplification and subsequent 
allelic discrimination using the C____779820_10, C___1622754_10, C__22273997_10, 
C___1622732_10, C__11648357_10, C___2143199_10, C__27484000_10, 
C____779802_10, C___1622768_10, C____779826_10 genotyping assays according to 
the manufacturers instructions (Applied Biosystems, Foster City, CA, USA) as described 
previously (15).  
Haplotype analysis. For the 126 included patients, TCGA provides genotype data for 
matched normal tissue using the Affymetrix Genome-Wide Human SNP Array 6.0 with 
906,000 probes. We performed a standard quality control step, by considering only 
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genotype calls with at least 95% confidence as reported by the Birdseed genotyping 
algorithm. We then selected SNPs with high-confidence genotype calls (SNP call-rate of 
at least 80%, MAF≥0.05, p-value≥1E-4 for the Hardy-Weinberg Equilibrium test). With 
these parameters, our final dataset consisted of forty-four SNPs in the CD44 gene.  
Statistical analysis. Cox proportional hazards models were utilized to estimate the 
impact of SNP genotype on tumor-related death. The CD44 SNPrs187115 genotype was 
modeled as a categorical variable, with the T/T genotype being used as baseline. We also 
accounted for other prognostic factors that are relevant for PDAC, namely AJCC Stage 
(I, II, III, IV) and surgical margin status (R0, R1, R2); for these predictors, the baseline 
levels were set to II and R0, respectively. We then used the Wald-test to assess the 
statistical significance of the regression coefficients of the predictors in our model; 
predictors with p<0.05 were considered significant. Finally, for each model, we also 
tested that proportional hazards assumptions for Cox regression are verified, and found 
that all models verify these assumptions. Estimates for survival were calculated using 
Kaplan-Meier analysis and the log-rank test. The Likelihood ratio test was used to 
compare the goodness of fit of the tested models. The Fisher´s Exact Test and the Chi-
Square test statistics were used for the cross-tabulation analysis. A Jonckeere-Terpstra 
test was utilized to assess the median differences in the age of PDAC diagnosis. Missing 
data were handled on a complete-case analysis basis. Values for p<0.05 were considered 
significant. All analyses were performed using SPSS 22.0 software (SPSS Inc., Chicago, 
IL, USA) and the Manual Survival-Package as provided in the R statistical software („A 
Package for Survival Analysis in S“, Terry Therneau, 2015, v2.38, {http://CRAN.R-
project.org/package=survival}).  
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Results 
 
CD44 SNPrs187115 and PDAC survival  
 
First, we study the effects of CD44 SNPrs187115 (15) on the survival of patients 
with PDAC who underwent resection of their tumors and determine the genotype of the 
SNPrs187115 locus in 121 patients from our Swiss cohort. We start our analysis with a 
Kaplan-Meier survival estimate based only on the patient genotypes. At this stage of the 
analysis, other important clinical/histopathological factors that are known to affect the 
prognosis, i.e. tumor stage and completeness of surgical resection, are not included, in 
order to give a preliminary estimate of survival times for CD44 SNPrs187115. In line with 
the previously reported results in the NCI60 anticancer drug screen and the clinical 
phenotype observed in soft-tissue sarcomas, we observe a trend whereby the C/C 
genotype of CD44 SNPrs187115 associates with the shortest estimated survival time (Table 
2). Due to the expected inhomogeneity of the cohort regarding tumor stage and surgical 
margin status (R-status), which is inherent in most if not all clinical human datasets 
studying resectable PDAC, and the fact that Kaplan-Meier calculations can strongly 
under- or overestimate an effect of any single factor, we perform a multivariate survival 
analysis based on the Cox proportional hazards models. Indeed, in this analysis, which is 
adjusted for the known prognostic factors of PDAC, AJCC-stage and R-status and thus 
accounts for the heterogeneity of the cohort, the C/C genotype of CD44 SNPrs187115 
associates with a significantly worse prognosis. Hereby, those PDAC patients with a C/C 
genotype have a 2.38-fold (p=0.020) increased risk for tumor-related death compared to 
those homozygous for the major T-allele (Figure 1A, Table 3).  
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Next, in order to validate these results, we include a second, independent PDAC 
cohort from Germany (University Hospital of Ulm) that comprises of a total of 101 
patients who underwent pancreatic resection, the same cohort in which we have first 
described the gender-specific effects of a well-described polymorphisms in the MDM2 
gene (MDM2 SNP309) on pancreatic cancer risk and prognosis (16, 17). Strikingly, in 
close similarity to the Swiss cohort, those patients from the German cohort homozygous 
for the C-allele of CD44 SNPrs187115 have a significantly worse prognosis compared to 
those T/T in genotype with a 2.32-fold (p=0.044) increased risk for tumor-related death 
(Cox multivariate analysis; Figure 1B and Table 3). Correspondingly, a Kaplan-Meier 
survival estimate demonstrates a bias towards the shortest survival time for patients with 
a C/C genotype (Table 2).  
Subsequently, we are interested in validating the observations we have made in 
our German and Swiss cohorts, in a third and independent, publicly available dataset, The 
Cancer Genome Atlas (TCGA) pancreatic cancer database (https://tcga-
data.nci.nih.gov/tcga/tcgaHome2.jsp) (18). This database is supervised by the National 
Cancer Institute (funded by the US government) and comprises, among other tumor 
types, 126 PDAC patients who underwent surgical resection for their tumors and for 
whom normal tissue as well as a full clinical dataset is available (18). A thorough clinical 
and molecular characterization of the patients and their tumors has been done, including 
an extensive SNP-genotyping effort. Interestingly, again fully in line with all our 
previous observations, we note that the C/C genotype of CD44 SNPrs187115 correlates 
significantly with poorer survival in the TCGA cohort. Specifically, in those 126 PDAC 
patients from the TCGA database who underwent surgical resection of their primary 
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pancreatic tumors, patients with a C/C genotype associate with a 2.36-fold increased risk 
for tumor-related death compared to those with a T/T-genotype (p=0.044, Cox 
multivariate analysis, Figure 1C and Table 3). In line with the other cohorts, a Kaplan-
Meier survival estimate demonstrates a trend whereby the shortest estimated survival 
time is noted in patients with a C/C genotype (Table 2). Those results were equally 
pronounced in those 104 Swiss, 52 German and 85 patients from the TCGA cohort who 
received radio-/chemotherapy, albeit possibly due to a reduced sample size not 
statistically significant (Supplementary Table S1).  
In order to exclude that the observed effect of CD44 SNPrs187115 is caused by an 
enrichment of the C-allele in patients with advanced disease stages at the time of 
diagnosis or an incomplete tumor resection, we perform a cross-tabulation analysis in all 
three study cohorts utilizing a Fisher´s Exact test. We observe no significant enrichment 
of any of the genotypes in any AJCC stage or R-status of the tumors, further supporting 
the hypothesis that SNPrs187115 can serve as an independent predictor of survival 
(Supplementary Tables S2 and S3).  
Lastly, we perform a direct comparison of the predictive power of the SNP and 
the two other clinical factors (R-status and AJCC stage). To do this in a way that would 
not be limited in statistical power, we perform a survival analysis after merging the three 
cohorts in which we have noted the significant association of CD44 SNPrs187115 with 
differential survival. Together, the resulting cohort consists of 348 patients with 206 
tumor-related deaths. When we perform a Kaplan-Meier analysis using as predictors 
CD44 SNPrs187115, R-status and AJCC status independently, we are able to determine that 
all three predictors are statistically significant (CD44 SNPrs187115 p-value: 8.95E-3; R-
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status p-value: 1.34E-5; AJCC status: 2.05E-11; Table 4, Supplementary Figure S1). 
Analogously to the single cohort analysis, we perform a Cox regression to assess allelic 
differences in risk for CD44 SNPrs187115, adjusting for R-status and AJCC stage. We find 
that the patients with C/C genotype have a 2.19-fold increase in risk of tumor-related 
death compared to patients with T/T genotype (p-value: 5.6E-4, Table 3, Figure 1D). To 
further assess the significance and the predictive power of CD44 SNPrs187115, we perform 
a likelihood ratio test between our model, and a reduced model that considers only R-
status and AJCC status (Supplementary Table S4). We observe that our model, which 
includes CD44 SNPrs187115, fits significantly better than the reduced one with a p-value of 
4.97E-3, suggesting that the inclusion of the genotypes at this locus together with the 
clinical predictors will have greater predictive power than the clinical information alone. 
 
CD44 fine-mapping analysis 
 
Next, we are interested whether any potential functional polymorphism in high 
linkage disequilibrium (LD) with SNPrs187115 shows an even stronger association with 
PDAC survival. To this end, we first search for SNPs that are linked to SNPrs187115 
utilizing genotype data from European populations in 1000 Genomes Phase 1, and then 
retrieve their genotypes from the TCGA dataset to subsequently perform survival 
analyses. Of the forty-four polymorphisms that are located within the CD44 gene locus, 
we find SNPrs187115 to be in high linkage disequilibrium (LD) with 4 other SNPs 
(rs353620, rs353615, rs353623 and rs353618) (r2≥0.7; Figure 2). We then perform a 
survival analysis independently for each SNP, assuming a dominant model for each of the 
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two alleles (allele A and allele B) in order to screen for SNPs that might serve as even 
better predictors of PDAC survival than rs187115. In this dominant model, the T-allele of 
SNPrs187115 associates with a significant decrease in the risk of tumor-related death 
compared to the C/C genotype, which is consistent with the previous finding of C/C 
genotype being associated with higher risk (Cox multivariate analysis; HR: 0.441; 
p=0.043; Supplementary Table S5). In line with the linkage analysis, all SNPs from the 
haplotype tagged by rs187115 associate with allelic differences in risk for tumor-related 
death (Figure 2; Supplementary Table S5, up-to p=0.003, hazard ratio (HR)=0.288 (SNP 
rs353615)). Next, we determine the genotypes of the other SNPs from the rs187115 LD 
block, rs353615 and rs353623 that could add predictive value to the model, in our Swiss 
PDAC cohort. However, in contrast to SNPrs187115, the slight improvement in predictive 
value observed in the TCGA cohort for some of those SNPs cannot be replicated in the 
Swiss patients (Supplementary Table S6; up-to p=0.037, HR=0.459 for SNP rs353623 as 
compared to HR=0.428, p=0.018 for rs187115), demonstrating that SNPrs187115 indeed 
shows the strongest association with tumor-related death and the most consistent 
predictive value after PDAC resection within this haplotype.  
 Next, we expand the analysis to include SNPs within the entire genomic region of 
CD44 that tag other haplotypes than the rs187115 LD block (r2<0.7). The remaining 39 
tag SNPs cover all major haplotypes within the CD44 gene (LD block-size >3; r2≥0.8, 
Figure 2). Again assuming a dominant model for each of the two alleles, 11 of the 39 
polymorphisms show allelic differences in the risk for tumor-related death (Figure 2; 
Supplementary Table S5; up-to p=0.005, HR=0.406 for SNP rs353647). Together, those 
11 SNPs represent 8 different LD blocks within the CD44 gene (tagged by rs353630, 
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rs353647, rs1547060, rs11033019, rs2065006, rs10768114, rs353632 and rs3794110). 
We determine the genotypes of SNPs that tag 7 of those haplotype blocks in our Swiss 
cohort and repeat the survival analysis (one LD block tagged by rs353632 could not be 
determined due to the unavailability of an appropriate allelic discrimination assay). None 
of the effects of the SNPs can be validated in the Swiss cohort (Supplementary Table S6), 
suggesting that of all haplotypes included in the analysis, the LD block tagged by 
SNPrs187115 has indeed the strongest predictive value after PDAC resection. 
 
CD44 SNPrs187115 and PDAC risk 
 
Lastly, we test the hypothesis that the C-allele of CD44 SNPrs187115, which has 
been previously shown to associate with age-dependent increased risk for soft-tissue 
sarcoma (15), also associates with an increased risk for PDAC. Hereby, no significant 
differences between the SNPrs187115 genotypes are observed between 498 German blood 
donors and 101 German PDAC patients of the same ethnic background; no significant 
differences are noted for an age-dependent risk for PDAC (Supplementary Tables S7 and 
S8). In sum, the results do not support the hypothesis that SNPrs187115 affects the risk for 
the development of PDAC.  
 
Discussion 
 
Taken together, these observations strongly suggest that CD44 SNPrs187115 can 
serve as a predictive biomarker in patients with PDAC amenable to pancreatic resection. 
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Hereby, the C/C genotype of CD44 SNPrs187115 associates with an up-to 2.38-fold, 
significantly increased risk for tumor-related death in our Swiss discovery cohort. This 
observation is subsequently validated in two independent study cohorts, including the 
publicly available TCGA pancreatic cancer database supervised by the NCI.  
The genotype of CD44 SNPrs187115 can be determined before the initiation of any 
treatment by a simple blood test, which is readily available at the time of diagnosis and 
utilized to identify patients who are at higher risk for faster tumor progression. In contrast 
to CD44 SNPrs187115, other important prognostic factors currently in clinical use, such as 
completeness of resection and lymph node involvement, or those suggested to be useful 
in a clinical setting, such as postoperative CA19-9 serum levels (19), can only be 
accurately determined after surgical resection, and have therefore limited impact on 
therapeutic decisions.  
Our data strongly suggest that patients with a C/C genotype at the CD44 
SNPrs187115 locus with PDAC are less likely to have a good oncologic outcome after 
surgical treatment even in a resectable stage, and therefore should be considered for 
alternative systemic therapy or chemo-/radiotherapy protocols. Indeed, future 
adjuvant/neoadjuvant chemotherapy trials in resectable PDAC should stratify patients by 
the CD44 SNPrs187115 genotype and/or possibly exclude patients homozygous for the C-
allele.  
Importantly, CD44 SNPrs187115 also has a strong potential to serve as a biomarker 
signature that identifies patients with borderline resectable/locally advanced tumors, 
which could truly profit from established, more radical surgical therapies. These therapies 
aim to fully remove the tumors and therefore offer the only potential for cure in cases of 
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pancreatic cancer with a relatively favorable prognosis despite their locally advanced 
presentation. This is based on the fact that individuals who receive a resection of their 
tumors have an average life expectancy of approximately 23 months as compared to 11 
months for those with locally advanced, non-metastatic disease who may be considered 
for potentially curative tumor resection and instead undergo palliative treatment (4, 20, 
21). In fact, 50% of the tumors are classified as localized, and a large majority of these 
non-metastatic tumors (35% of all PDAC patients) are diagnosed in a borderline 
resectable or locally advanced stage. Despite technical resectability in many of those 
cases, they are only rarely considered for surgical resection. Therefore, curative treatment 
is currently offered only to the remaining 15% of the non-metastatic patients (2, 4). Such 
a restrictive surgical strategy is mainly caused by the observation that extended types of 
resection, which involve major visceral vessel resection and reconstruction, can lead to an 
increased perioperative morbidity and mortality (5, 22-24). However, due to the fact that 
extended surgical procedures offer the only chance for a cure and are technically feasible, 
they have been strongly advocated in the literature (5, 22-24). It is thought that these 
procedures are particularly useful in a subset of patients that are expected to have a 
relatively good long-term prognosis, such as individuals who carry the T-allele of CD44 
SNPrs187115, and who might truly benefit from a potentially curative therapy, as the 
expected long-term benefit would outweigh the increased perioperative risk. It will be 
important to study whether the findings of this analysis, which is limited to patients 
without locally advanced disease, can be repeated in a clinical trial in individuals with 
locally advanced/borderline resectable PDAC who undergo resection in curative intent.  
In contrast to our previous study performed in the NCI60 cell line panel (which 
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does not include pancreatic cancer cells) and soft-tissue sarcoma patients (15), we 
observe that the association of CD44 SNPrs187115 and survival in PDAC is equally 
pronounced in patients who received DNA-damaging treatments and those who only 
underwent resection of their tumors. However, this observation is possibly due to 
differences in the biology of the tumors and their susceptibility to chemo- and/or 
radiotherapy. Hereby, in contrast to soft-tissue sarcomas, which are known to respond 
well to DNA-damaging treatments (25-28), the effect of such therapies is only very 
limited in resectable PDAC and most clinical studies have shown no or only a weak 
response to the agents utilized in the treatment of the patients included in our study (29-
32).  
In addition, besides the above-described impact on surgical strategy, CD44 SNP 
also has the potential to affect the medical treatment of the patients. This is based on the 
recent observation that CD44 can be successfully directly targeted in pancreatic 
adenocarcinoma with monoclonal antibodies to treat pancreatic xenograft tumors in mice 
(33, 34). Based on those findings, clinical trials in humans utilizing this approach are 
already under way (33, 34). Moreover, it has been shown that CD44 interacts with the 
EGFR receptor, which is already an FDA-approved therapeutic target in PDAC, to 
promote cell motility and invasiveness (35, 36). Therefore, it is tempting to speculate that 
the identified SNP in the CD44 gene could affect the response to current and future 
targeted therapies, such as direct anti-CD44 targeting or EGFR inhibition. It will be 
interesting to test this hypothesis in future clinical trials that utilize such novel therapeutic 
approaches. In addition, it will be important to elucidate the precise molecular 
mechanisms by which this SNP leads to the observed clinical phenotypes and to test its 
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potential to affect cellular signaling pathways that can be directly targeted by modern 
therapeutics.  
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 Figure legends 
 
 
 
Figure 1. Cox multivariate analysis of tumor-specific survival after resection of 
pancreatic ductal adenocarcinoma (PDAC). The C/C genotype of the CD44 SNP, 
which has been previously shown to associate with a weaker apoptotic response to 
chemotherapeutic treatment in the NCI60 cell lines and with a poorer survival in soft-
tissue sarcoma patients (15) also correlates significantly with poorer survival in PDAC 
patients. (A) The Figure shows the results of the Cox analysis in 121 PDAC patients from 
Switzerland who underwent a surgical resection of their primary pancreatic tumors. 
Patients with a C/C genotype associated with the shortest survival time compared to those 
with a T/T-genotype (HR=2.38 for tumor-related death). (B) Results of the Cox analysis 
in 101 PDAC patients from Germany who underwent a surgical resection of their tumors 
at the University Hospital of Ulm. Patients with a C/C genotype had the shortest survival 
time compared to those with a T/T-genotype (HR=2.32). (C) The graph displays the 
survival curves of 126 PDAC patients from the publicly available TCGA database who 
underwent resection of their tumors. Patients with a C/C genotype associate with a 2.36-
fold increased risk for tumor-related death compared to those T/T in genotype (Cox 
multivariate regression analysis, adjusted for the known prognostic factors of PDAC 
AJCC stage and resection margin). (D) Survival analysis in the merged dataset (all 3 
PDAC cohorts: Swiss, German, TCGA) with a total of 348 patients.  
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Figure 2. CD44 fine-mapping: Cox survival analysis of CD44 SNPs in the TCGA 
PDAC cohort. For each SNP, we plot the best p-value of the Cox regression on the 
dominant models for the A and B alleles; the black dashed line is the p-value ≤ 0.05 
significance threshold. Each SNP is plotted at its genomic locus, according with the hg19 
human genome assembly. The rs187115 LD Block (r2 ≥ 0.7, 5 SNPs) is the one showing 
the most significant associations with differential survival. All of the SNPs from the 
rs187115 LD Block are located within intron 1 of the CD44 gene.  
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Tables 
 
Table 1. Clinical and histopathological data.  
Swiss cohort German cohort TCGA cohort Merged          (all 3 cohorts)
Median age*
66 yrs  (19-87) 65 yrs (32-82) 65.5 yrs (35-85) 65 yrs (19-87)
Median observation time*
20.2 mo (1-89) 12.0 mo (1-85) 12.4 mo (0-66) 13 mo (0-89)
Frequency of cases assessed for inclusion 154 253 185 592
Frequency of included cases (%)
Total 121 101 126 348
Females 63 (52.1) 40 (39.6) 56 (44.4) 159 (45.7)
Males 58 (47.9) 61 (60.4) 70 (55.6) 189 (54.3)
Frequency of excluded cases (%)
Total excluded 33 152 59 244
Missing follow-up 2 (6.1) 0 (0) 5 (8.5) 7 (2.9)
No normal tissue and/or blood 2 (6.1) 14 (9.2) 18 (30.5) 34 (13.9)
Missing histopathologic data 0 (0) 1 (0.7) 9 (15.2) 10 (4.1)
Histology other than PDAC 0 (0) 137 (90.1) 27 (45.8) 164 (67.2)
No pancreatic resection 29 (87.9) 0 (0) 0 (0) 29 (11.9)
Status at last follow up (%)
Died of tumour-related causes 71 (58.7) 77 (76.2) 59 (46.8) 207 (59.5)
Alive 36 (29.8) 20 (19.8) 58 (46.0) 114 (32.8)
Died of non tumour-related causes 4 (3.2) 0 (0) 7 (5.6) 11 (3.2)
In-hospital death 10 (8.3) 4 (4.0) 2 (1.6) 16 (4.6)
Chemo- and/or radiotherapy (%)**
104 (86.0) 52 (51.5) 85 (67.5) 241 (69.3)
Stage (%)
I 4 (3.3) 7 (6.9) 10 (7.9) 21 (6.0)
II 103 (85.1) 82 (81.2) 108 (85.7) 293 (84.2)
III 6 (5.0) 4 (4.0) 4 (3.2) 14 (4.0)
IV 8 (6.6) 8 (7.9) 4 (3.2) 20 (5.7)
Tumour resection (%)***
Radical (R0) 66 (54.5) 73 (72.3) 82 (65.1) 221 (63.7)
Not radical (R1) 48 (39.7) 17 (16.8) 42 (33.3) 107 (30.8)
Not radical (R2) 7 (5.8) 10 (9.9) 2 (1.6) 19 (5.5)
yrs=years; mo=months
* Included cases only; the range is given in brackets
*** The R-Status of one patient (German cohort) could not be determined
** The chemotherapeutic agents included Gemcitabine, Oxaliplatin, Capecitabine,Irinotecan, 5-FU, Leucovirin (Swiss 
cohort), Gemicitabine (German cohort) and Gemcitabine, Oxaliplatin, Capecitabine, Irinotecan, 5-FU, Paclitaxel, 
Doxorubicin, Cyclophosphamide, Leucovirin (TCGA)
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Table 2. Medians for survival time based on Kaplan Meier estimates (not adjusted to 
AJCC Stage and R-Status) 
Lower 
Bound
Upper 
Bound
T/T 67 39 26.5 6.2 14.3 38.7
T/C 39 22 20.0 1.9 16.3 23.7
C/C 15 10 17.0 3.8 9.5 24.5
T/T 43 28 15.0 1.4 12.2 17.8
T/C 47 39 14.0 1.8 10.5 17.5
C/C 11 9 12.0 NA NA NA
T/T 58 24 20.0 1.4 17.3 22.6
T/C 54 27 20.2 1.8 16.7 23.6
C/C 14 8 15.8 5.9 4.2 27.4
Estimate 
(months) Std. Error
CD44 
rs187115 n
p-value    
(log-rank)
0.124
0.287
Swiss
Number of 
tumour-
related 
deaths
0.325
German
TCGA
95% Confidence Interval
Medians
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 28
Table 3. Cox multivariate regression analysis. 
Cohort Adjustment variable n Hazard Ratio
95% 
Confidence 
Interval
P-value
CD44 SNP rs187115
 T/T 67 1 - -
C/T 39 1.043 0.604 - 1.802 >0.1
C/C 15 2.380 1.143 - 4.940 0.020
R-status
R0 66 1 - -
R1 48 1.378 0.820 - 2.320 >0.1
R2 7 13.462 3.186 - 56.972 0.000
AJCC Stage
I 4 0.571 0.079 - 4.146 >0.1
II 103 1 - -
III 6 0.401 0.077 - 2.078 >0.1
IV 8 0.976 0.331 - 2.870 >0.1
CD44 SNP rs187115
 T/T 43 1 - -
C/T 47 1.516 0.891 - 2.581 >0.1
C/C 11 2.320 1.022 - 5.270 0.044
R-status
R0 73 1 - -
R1 17 1.106 0.572 - 2.138 >0.1
R2 10 1.724 0.374 - 7.941 >0.1
AJCC Stage
I 7 0.626 0.181 - 2.159 >0.1
II 82 1 - -
III 4 6.040 1.786 - 20.429 0.004
IV 8 4.004 0.777 - 20.630 0.097
CD44 SNP rs187115
 T/T 58 1 - -
C/T 54 1.094 0.608 - 1.970 >0.1
C/C 14 2.361 1.023 - 5.449 0.044
R-status
R0 82 1 - -
R1 42 2.025 1.124 - 3.647 0.019
R2 2 NA NA >0.1
AJCC Stage
I 10 0.580 0.171 - 1.972 >0.1
II 108 1 - -
III 4 2.315 0.536 - 10.003 >0.1
IV 4 1.506 0.458 - 4.953 >0.1
CD44 SNP rs187115
 T/T 168 1 - -
C/T 140 1.213 0.902 - 1.631 >0.1
C/C 40 2.188 1.402 - 3.415 0.001
R-status
R0 221 1 - -
R1 107 1.327 0.969 - 1.818 0.078
R2 19 4.056 2.001 - 8.220 0.000
AJCC Stage
I 21 0.610 0.284 - 1.308 >0.1
II 293 1 - -
III 14 1.501 0.689 - 3.269 >0.1
IV 20 1.536 0.858 - 2.751 >0.1
Swiss
German
TCGA
Merged              
(all 3 cohorts)
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Table 4. Survival time analysis in the merged database including all 3 PDAC cohorts 
based on Kaplan Meier estimates 
Lower 
Bound
Upper 
Bound
T/T 168 91 20.6 1.8 17.1 24.2
T/C 140 88 18.0 1.6 14.8 21.2
C/C 40 27 15.8 2.6 10.7 20.8
1 21 7 NA NA NA NA
2 293 172 20.0 1.5 17.1 22.8
3 14 10 13.0 0.8 11.4 14.5
4 20 17 12.0 4.7 2.9 21.1
0 221 126 20.2 1.7 16.9 23.4
1 107 64 18.0 1.7 14.7 21.3
2 19 16 5.0 1.0 3.0 7.0
n
Number of 
tumour-related 
deaths
Medians
Estimate 
(months) Std. Error
95% Confidence Interval
CD44 
rs187115
AJCC
R-status
p-value    
(log-rank)
0.009
0.000
0.000
Group
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